Safety and efficacy study of umbilical cord-derived mesenchymal stem cells for rheumatoid arthritis
Overview:
This phase 1/2 study commenced in April 2013 and is being conducted
at The 323 Hospital of Chinese People’s Liberation Army. The purpose
of this study is to explore the safety and effectiveness of human
umbilical cord–derived mesenchymal stem cell (UC-MSCs)
transplantation in the treatment of rheumatoid arthritis (RA).
Researchers are investigating whether the anti-inflammatory effects of UC-MSCs will alleviate the progression of RA in adult patients. Investigators aim to recruit 200 adult participants with RA between the ages of 18 and 70 years to undergo intravenous infusions of UC-MSCs every 3 months for a total of 2 months (4 infusions in total). A comparison group will receive conventional RA drugs and a final comparator group will receive both UC-MSCs and conventional RA drugs.
Location: Shaanxi, China
Trial design Safety and efficacy
Status: Recruiting
Find out more